Alfredo Giacchetti

Alfredo Giacchetti

Auto-generated profile, based on publicly available information

Alfredo Giacchetti

Dermatology Unit Istituto Nazionale di Riposo e Cura per Anziani INRCA‐IRCCS Hospital Ancona Italy

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2007 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
MTM.G. Tucci
M.G. Tucci
Guendalina LucariniGuendalina Lucarini
Guendalina Lucarini
DBD. Brancorsini
D. Brancorsini
AZA. Zizzi
A. Zizzi
APA. Pugnaloni
A. Pugnaloni
GBG. Biagini
G. Biagini

5 July 2005 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
SRSerena Rupoli
Serena Rupoli
GGGaia Goteri
Gaia Goteri
SPStefano Pulini
Stefano Pulini
AFAlessandra Filosa
Alessandra Filosa
ATAngela Tassetti
Angela Tassetti
(L(for the Marche Regional Multicentric Study Group of Cutaneous Lymphomas)
(for the Marche Regional Multicentric Study Group of Cutaneous Lymphomas)

1 May 2007 in Haematologica
Verified
Journal Article
Closed access
PDF file
SPS. Pulini
S. Pulini
SRS. Rupoli
S. Rupoli
GGG. Goteri
G. Goteri
NPN. Pimpinelli
N. Pimpinelli
RAR. Alterini
R. Alterini
PLP. Leoni
P. Leoni
Pegylated liposomal doxorubicin (Peg-Doxo) is a promising drug for advanced/recalcitrant primary cutaneous T-cell lymphomas (CTCLs). This prospective phase II trial enrolled 19 patients. We observed overall and complete response rates of 84.2% and 42.1% (with no significant differences between stage I–IIA and IIB–IV patients), and 11% grade III/IV toxicity. After a maximum 46 month-follow-up, median overall (OS), event-free (EFS) and progression-free (PFS) survival were 34, 18 and 19 months. OS, EFS and PFS rates at 46 months were 44%, 30% and 37% respectively. Peg-Doxo seems to be an active and safe principle that should be used in plurirelapsed, early stage-MF and in combination with other chemotherapeutic agents in advanced and aggressive CTCLs.

1 September 2007 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
GGGaia Goteri
Gaia Goteri
SRS. Rupoli
S. Rupoli
DSD. Stramazzotti
D. Stramazzotti
GDG. Discepoli
G. Discepoli
ASA.R. Scortechini
A.R. Scortechini
PLP. Leoni
P. Leoni

1 May 1986 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
PPP.D. Pigatto
P.D. Pigatto
MPM.M. Polenghi
M.M. Polenghi
GAG.F. Altomare
G.F. Altomare
AGA. Giacchetti
A. Giacchetti
RCR. Cirillo
R. Cirillo
AFA.F. Finzi
A.F. Finzi

3 September 2018 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
ACA. Capo
A. Capo
GGG. Goteri
G. Goteri
GMG. Mozzicafreddo
G. Mozzicafreddo
SSS. Serresi
S. Serresi
AGA. Giacchetti
A. Giacchetti